China Pharma Holdings Profit Margin

China Pharma Holdings posts a profit margin of -84.67% as of March 2026. That compares with -105.7% in the prior-year period — up 19.9% year over year. That is below the Healthcare sector average of 14.34%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, China Pharma Holdings's profit margin was -105.7%. The latest reading is -84.67% — a 19.9% year-over-year increase (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 14.34% is typical. China Pharma Holdings's -84.67% is lower that level. That is roughly 690.3% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

China Pharma Holdings's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -84.67% as of March 2026; use YoY and peer views to separate noise from signal.

Context for CPHI's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 14.34%), and (3) consistency with growth and profitability. This page covers the first two; China Pharma Holdings's other metric pages and overview cover the third.